Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Obstetrics and Gynecology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief, No 327.National Center for Health Statistics, Hyattsville, MD2018
- Contraceptive methods women have ever used: United States, 1982-2010.Natl Health Stat Rep. 2013; : 1-15
- Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: a new year-long, patient controlled, reversible birth control method.Expert Rev Clin Pharmacol. 2019; 12: 953-963
- Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation.Contraception. 2019; 99: 323-328
- Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.Hum Reprod. 2005; 20: 557-562
- Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.Contraception. 2018; 97: 270-276
- Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.Am J Obstet Gynecol. 2015; 212: 318.e1-318.e8
- Efficacy and safety of a transdermal contraceptive system.Obstet Gynecol. 2001; 98: 799-805
- Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.J Clin Pharmacol. 2001; 41: 1301-1309
- Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.Contraception. 2013; 87: 212-219
- Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.Contraception. 2017; 95: 130-139
- Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.Fertil Steril. 2002; 77: S13-S18
- Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability.Contraception. 2015; 92: 439-444
- Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake.Contraception. 2016; 93: 303-309
- Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.Contraception. 2000; 62: 29-38
- DMPA-SC: an emerging option to increase women's contraceptive choices.Contraception. 2018; 98: 375-378
- An overview of properties of Amphora (Acidform) contraceptive vaginal gel.Expert Opin Drug Saf. 2018; 17: 935-943
- A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial.Contracept X. 2020; 2: 100031
- Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two-rod contraceptive implant over 4 years in the Dominican Republic.Contracept X. 2019; 1: 100006
- The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience.Contraception. 2017; 95: 205-210
- Real world data on Nexplanon® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA).Contraception. 2019; 100: 31-36
- Neurovascular anatomy of the adult female medial arm in relationship to potential sites for insertion of the etonogestrel contraceptive implant.Contraception. 2019; 100: 26-30
- Society of family planning clinical recommendations: contraception after surgical abortion.Contraception. 2019; 99: 2-9
- Society of family planning guidelines: postplacental insertion of intrauterine devices.Contraception. 2018; 97: 2-13
- Early versus delayed insertion of intrauterine contraception after medical abortion—a randomized controlled trial.PLoS One. 2012; 7: e48948
- Timing of copper intrauterine device insertion after medical abortion: a randomized controlled trial.Obstet Gynecol. 2011; 118: 623-628
- Immediate versus delayed IUD insertion after uterine aspiration.N Engl J Med. 2011; 364: 2208-2217
- Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial.Obstet Gynecol. 2010; 116: 1079-1087
- New and emerging female contraceptives expand options.in: Society of Family Planning annual meeting; 2020 October 7. 2020 (Virtual Conference via Zoom)
- Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.Eur J Contracept Reprod Health Care. 2017; 22: 260-267
- P44 Phase 3 clinical trial results of a new combined oral contraceptive with estetrol 15 MG and drospirenone 3 MG.Contraception. 2020; 102: 291
- Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.Circulation. 2007; 115: 840-845
- Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate.Contraception. 2020; 102: 168-173
- Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.Contraception. 2018; 97: 422-427
- Nestorone® as a novel progestin for nonoral contraception: structure-activity relationships and brain metabolism studies.Endocrinology. 2017; 158: 170-182
- Ovarian function during use of vaginal rings delivering three different doses of Nestorone.Contraception. 2001; 63: 257-261
- Progesterone vaginal ring as a new contraceptive option for lactating mothers: evidence from a multicenter non-randomized comparative clinical trial in India.Contraception. 2020; 102: 159-167
- Ovulation inhibition with a new vaginal ring containing trimegestone.Contraception. 2020; 102: 237-242
- Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.Contraception. 2012; 85: 480-488
- Uterine fibroid drug is recalled after case of liver failure requiring transplant prompts EU review.BMJ. 2020; 368: m1112
- A randomized comparison of a novel nitinol-frame low-dose-copper intrauterine contraceptive and a copper T380S intrauterine contraceptive.Contraception. 2017; 95: 544-548
- Efficacy, safety, and tolerability of a new low-dose copper and nitinol intrauterine device: phase 2 data to 36 months.Obstet Gynecol. 2020; 135: 840-847
- Intrauterine contraception.Semin Reprod Med. 2016; 34: 175-182
- New developments in intrauterine device use: focus on the US.Open Access J Contracept. 2016; 7: 127-141
- Rapidly separable microneedle patch for the sustained release of a contraceptive.Nat Biomed Eng. 2019; 3: 220-229
- A once-a-month oral contraceptive.Sci Transl Med. 2019; 11: eaay2602
- Pharmaceutical jewelry: earring patch for transdermal delivery of contraceptive hormone.J Control Release. 2019; 301: 140-145
- End-users' product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa.AIDS Behav. 2018; 22: 133-145
- Multipurpose prevention technologies: products in development.Antivir Res. 2013; : S39-S47
- Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device.J Control Release. 2016; 226: 138-147
- Antibody-based contraceptive MPTS: preclinical and clinical research.National Institute of Health, 2020 (Available at:)
- Next generation multiputpose prevention technology: an intravaginal ring for HIV prevention and nonhormonal contraception.National Institute of Health, 2020 (Available at:)
- O4 The levonorgestrel vs. copper intrauterine device for emergency contraception: a non-inferiority randomized controlled trial.Contraception. 2020; 102: 274
- Copper intrauterine device placement 6-14 days after unprotected sex.Contraception. 2019; 100: 219-221
- What is it about intrauterine devices that women find unacceptable? Factors that make women non-users: a qualitative study.J Fam Plann Reprod Health Care. 2006; 32: 89-94
- "$231 … to pull a string!!!" American IUD users' reasons for IUD self-removal: an analysis of internet forums.Contraception. 2020; 101: 393-398
- Interest in and experience with IUD self-removal.Contraception. 2014; 90: 54-59
- Effect of knowledge of self-removability of intrauterine contraceptives on uptake, continuation, and satisfaction.Womens Health Issues. 2018; 28: 68-74
Article info
Footnotes
A. L. Gilbert, has no conflicts of interest or financial ties to disclose.
B. L. Hoffman, has no relationships with the medical industry to disclose.
Funding source includes McGraw-Hill Education.
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
